Efficacy and safety of tixagevimab-cilgavimab (Evusheld®) in people with Multiple Sclerosis on Ocrelizumab: preliminary evidence.
Manuela AltieriRosario Domenico MelisiMiriana ConteRocco CapuanoGiovanna DonnarummaElena GrimaldiNicola CoppolaStefania De PascalisMario RisiAlessandro d'AmbrosioAlvino BiseccoAntonio GalloPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023)
These results further support EVS safety and efficacy in boosting anti-TSP IgG titers in pwMS on OCR, with a statistically greater increase than that observed after completion of a full Covid-19 vaccine cycle, plus a booster dose.